PGNY Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 1.93%, SMA50 -8.23%, SMA200 -2.35%). The stock’s 14-day RSI is 48.71 (neutral), while the ATR of 0.89 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -22.61% below its high and over 23.77% above its low. Average 10-day trading volume of 1.58 million shares is slightly above the 3-month average of 1.33 million, indicating heightened recent market interest.

Progyny, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $72.93. This means the shares are trading below this model’s fair value.

Progyny, Inc. (NASDAQ:PGNY) closed at $26.28 USD, gaining $0.39 (1.51%) from the previous close of $25.89. The stock is currently mid-range between its 52-week high and low $16.10 and $33.06. With a market capitalization of about $2.06 billion, Progyny, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.02). Key stats such as the average daily volume over the past year has been around 1.35 million shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, Progyny, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Pete Anevski, the company employs approximately 846 people and listed since October 25, 2019. Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States.

Progyny, Inc. has 78.33 million shares outstanding. The public float is 71.66 million shares, elevated short interest at 8.28% of float. This equals 4.63 million shares. The short ratio is 3.33 days. Institutional investors hold 113.75% of the float. Insiders own 1.95%. TPG GP A, LLC holds 6.35 million shares, Anevski Peter has 680.25 thousand shares and Sturmer Michael E has 362.58 thousand shares. Over the past six months, insider transactions show net selling. They sold 37.35 thousand shares across 11 transactions.

Wall Street analysts project EPS growth of 25.91% annually over the next five years. The latest quarter delivered EPS of $0.55. The next quarter is forecast at $0.15. Next year's EPS is expected at $22.05. Analyst sentiment is bullish. Analyst rating data shows there are 9 Strong Buy ratings, 8 Buy ratings, 6 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $23.00. The high target offers 52.21% upside. The low target suggests -12.48% downside. The mean target is $30.35. This offers 15.49% upside. Progyny, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 06, 2026, missed forecasts by 64.28%. The prior quarter beat by 13.28%. Over the last six quarters, Apple has recorded several small beats. These include 6.67% in May 08, 2025.

Progyny, Inc. trades at a P/E ratio of 27.09, slightly below the S&P 500 average, with a price-to-sales ratio of 1.57 and a price-to-book ratio of 4.53 trading at moderately above to book value. The P/FCF stands at 9.44, also above market averages.

Our AI price prediction model suggests that Progyny, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -38.09%, with price expected at $16.27 by August 28, 2026, within a range of $15.03 to $17.51 3-Month Outlook: Projected fall of -55.48%, reaching $11.70 by November 12, 2026, with a range of $10.12 to $12.72. 1-Year Outlook: Projected loss of -16.55%, with price at $21.93 by August 13, 2027, within a range of $19.85 to $24.31.

Progyny, Inc. (NASDAQ:PGNY) shares are flat -1.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Progyny, Inc. trading at a premium to the broader market with a P/E of 27.09. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $36.76, suggesting 39.88% upside. Our AI forecast model points to short-term weakness (-38.09% over two weeks), a medium-term fall (-55.48% over three months), and a longer-term loss (-16.55% over one year), with expected trading ranges indicating moderate volatility.